Validating Gulf War Illness Blood Biomarkers
Launched by ROSKAMP INSTITUTE INC. · Feb 9, 2023
Trial Information
Current as of July 23, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying Gulf War Illness (GWI) to identify specific blood markers that could help understand the condition better. Researchers want to see if certain fats and metabolites in the blood are linked to cognitive decline, especially in veterans who carry a specific gene known as APOE ε4. They will also look at how diet and other health factors affect these blood markers and how they relate to problems in the brain. The goal is to validate these blood markers as useful tools for diagnosing and understanding GWI.
To participate, you need to be at least 35 years old and have served in the Gulf War during 1990-1991, meeting specific criteria for GWI. If you’re a veteran without GWI, you can still join as a control participant. You must be able to understand and communicate in English. Participants will undergo tests that involve blood samples and may answer questions about their health and experiences. Importantly, those with certain serious health conditions, like cancer or significant psychiatric issues, will not be eligible to ensure everyone’s safety during the study.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Age 35 years or older.
- • 2. For GWI cases, served in the 1990-1991 Gulf War as active duty, national guard, or reserves and meet criteria for the CDC Chronic Multisymptom Illness (CMI) GWI definition or Kansas GWI definition.
- • 3. For controls, must be a veteran in the same age range as those veterans with GWI as defined above.
- • 4. Ability to understand written and spoken English or availability of a legal representative who can understand written or spoken English. Participants and caregiver/informants must be able to read, write and speak the language in which psychometric tests are provided with visual and auditory acuity (corrected) sufficient to allow for accurate testing.
- Exclusion Criteria:
- 1. Diagnosed or being treated by a physician for any of the following (Steele et al, 2000) and deemed clinically significant per the discretion of the PI:
- • 1. Cancer (except for non-melanoma skin cancers)
- • 2. Chronic infectious disease
- • 3. Problems resulting from postwar injuries.
- • 4. Liver disease
- • 5. Lupus
- • 6. Multiple sclerosis
- • 7. Stroke
- • 8. Serious psychiatric condition (those associated with psychosis and/or for which the respondent had been hospitalized since 1991).
- • 9. Dementia or any type of Parkinson's disease (PD).
- • 2. Hospitalized in the last 5 years for alcohol or drug dependence, depression, or post-traumatic stress disorder (PTSD).
- • 3. Female subject is either pregnant or nursing.
About Roskamp Institute Inc.
Roskamp Institute Inc. is a leading nonprofit research organization dedicated to advancing the understanding and treatment of neurocognitive disorders, primarily focusing on Alzheimer's disease and related conditions. With a commitment to innovative research and clinical trials, the Institute collaborates with esteemed academic institutions and industry partners to develop novel therapeutic approaches. Its multidisciplinary team of experts combines clinical expertise with cutting-edge scientific methodologies, striving to translate research findings into effective interventions that improve patient outcomes and enhance quality of life. Through its rigorous approach to clinical investigation, Roskamp Institute Inc. aims to contribute significantly to the field of neurodegenerative disease research and treatment.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Boston, Massachusetts, United States
Boston, Massachusetts, United States
Palo Alto, California, United States
Sarasota, Florida, United States
Patients applied
Trial Officials
Laila Abdullah, Ph.D.
Principal Investigator
The Roskamp Institute
Michael Hoffmann, MD
Principal Investigator
The Roskamp Institute
Kim Sullivan, Ph.D
Principal Investigator
Boston University
Maheen Adamson, Ph.D.
Principal Investigator
Palo Alto Veterans Institute of Research
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials